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Background: Spironolactone is often used to treat hypertension caused by hyperaldosteronism, and as a result, can
form concentrically laminated electron dense spironolactone body inclusions within the adrenal gland.
Spironolactone bodies have not been investigated in a contemporary cohort or in patients treated with the more
recently approved aldosterone antagonist, eplerenone.
Methods: Spironolactone bodies were retrospectively investigated in patients treated for hyperaldosteronism
(n = 15) from 2012-2013 that underwent a subsequent adrenalectomy.
Results: Inclusions were identified in 33% of patients treated with aldosterone antagonists, far less than previously
reported. Remarkably, 50% of patients treated with spironolactone had inclusions while no patients using
eplerenone alone had inclusions. Two patients treated with spironolactone had bodies present longer than the
duration described in prior studies. Inclusions unexpectedly persisted in 1 patient despite increased duration of
discontinued pharmacological treatment. A spectrum of histologic and ultrastructural findings were encountered
within an adrenal cortical adenoma from a patient treated with both spironolactone and eplerenone. Ultrastructural
examination revealed laminated electron dense bodies with the appearance of classic spironolactone inclusions as
well as electron dense bodies without laminations and laminated bodies without electron dense cores.
Conclusions: Our incidence rate of spironolactone bodies was much lower than previously reported, with no
inclusions seen in patients treated solely with the newer aldosterone antagonist, eplerenone. Pathologists should
be aware of these infrequently encountered inclusions, particularly as the clinical history of hyperaldosteronism and
pharmacologic treatment may not be provided.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/4597918761268031
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A common cause of primary hyperaldosteronism is an
aldosterone-producing adenoma, which is initially treated
with aldosterone antagonists such as spironolactone and
eplerenone. As spironolactone treatment may cause limit-
ing side effects, namely menstrual irregularities in women
and impotence, decreased libido, and gynecomastia in men,* Correspondence: debra.zynger@osumc.edu
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Adrenalectomy is performed if the drugs prove ineffective.
Spironolactone body formation has been well documented
and occurs within the adrenal gland secondary to spirono-
lactone treatment [1]. The composition of these bodies is
purported to be a high content of Luxol fast blue stain-
ing phospholipid and aldosterone in the outer concen-
tric laminations [2-4].
We investigated the incidence of spironolactone bodies
within a recent cohort of patients treated with aldosteroned. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with a lower frequency identified than in earlier studies. In-
clusion bodies were detected with extended use of spirono-
lactone and with longer periods of discontinued use, which
has not been previously reported. Additionally, we describe
the spectrum of histological and ultrastructural findings in
an aldosterone-producing adenoma from a patient treated
with both spironolactone and eplerenone. The ultrastruc-
tural features included bodies with spiral and non-spiral
membranes and bodies without membranes.
Methods
A retrospective search was performed to identify patients
treated with an adrenalectomy during a 2 year time period
(January 2012-December 2013) at our hospital with a clin-
ical history of hyperaldosteronism conducted in compli-
ance with our Institutional Review Board (The Ohio State
University Medical Center; Protocol #2002H0089) and in
compliance with the Helsinki Declaration. Aldosterone
antagonist treatment regimens were recorded. All slides
were reviewed using light microscopy to evaluate for the
presence of inclusions.
One patient with unusual inclusions was further inves-
tigated with immunohistochemical, special stains, and
ultrastructural examination (patient 1, described below).
Transmission electron microscopic examination was
performed for this patient using formalin-fixed tissue.
Formalin-fixed tissue was postfixed in glutaraldehyde
(1 hour) followed by aqueous osmium tetroxide (1 hour)
and uranyl acetate-lead citrate (1 hour). A second patient
with classic inclusions was further investigated with
ultrastructural examination using formalin-fixed paraffin-
embedded tissue (patient 2, described below). A represen-
tative area of the tumor was cut from the paraffin block.
The tissue was deparaffinized in 1% aqueous osmium
tetroxide dissolved in toluene (4 hours). Epoxy resin
infiltration was performed and the resin was polymer-
ized to make electron microscopic blocks. Blocks were
thin sectioned and examined with a JEOL JEM 1400
transmission electron microscope.
Results
Fifteen patients were identified that had an adrenalec-
tomy for serologically proven hyperaldosteronism. Six
patients were treated with spironolactone alone, 5 were
treated with eplerenone alone, 1 was treated with both
spironolactone and eplerenone, and 3 did not receive
pharmacologic therapy (Table 1). Inclusions were histo-
logically identified in 4 out of the 12 treated (33.3%) and
none of the untreated patients. The single patient with a
history of both spironolactone and eplerenone treatment
had unusual inclusions (patient 1). In the spironolactone-
only subgroup, 50% had inclusions (patients 2-4). No
patients using eplerenone alone had inclusions. Patient 1discontinued spironolactone more than 4 months before
surgery and was switched to eplerenone, which was discon-
tinued for more than 21 days before surgery. Despite being
off both medications for more than 3 weeks, inclusions were
found. Two of 3 patients given spironolactone alone for over
100 days had bodies, and 2 of these patients treated for
over 270 days had focal or diffuse bodies (patient 2 and 3).
Patient 1
A 39 year-old male with known high aldosterone presented
with complaint of abdominal pain. CT scan showed a
1.7 cm left adrenal lesion and a separate left lower pole kid-
ney mass. Robotic partial nephrectomy resected a papillary
type 1 renal cell carcinoma. Post-operative follow-up found
continuing levels of high aldosterone and the patient was
started on spironolactone (dose not documented). The
patient continued to have high levels of aldosterone at
6 weeks and was switched to eplerenone 50 mg/day.
Failure to lower aldosterone levels called for adrenal
vein sampling, which confirmed the left adrenal nodule
as the source of the hyperaldosteronism. Eplerenone
dosage was increased to 50 mg twice a day after 3 weeks,
then 50 mg twice in the morning and once at night after
an additional 3 weeks. The patient was taken off eplerenone
and underwent a unilateral adrenalectomy, resulting in the
resolution of the hyperaldosteronism.
A 19.8 g, 7.5 × 3.8 × 1.8 cm left adrenal gland with
attached adipose was serially sectioned to reveal a tan-
yellow, rubbery cortical nodule measuring 1.9 × 1.6 ×
1.5 cm (Figure 1). The mass was homogenous with no
areas of hemorrhage or necrosis, and did not involve
the periadrenal fat. Light microscopic examination of
hematoxylin and eosin stain stained slides demonstrated a
well circumscribed, unencapsulated mass composed of
nests of clear to eosinophilic adrenal cortical tumor cells
interspersed with degenerating bland adrenal cortical cells
(Figure 2A). Numerous brightly eosinophilic inclusions of
varying sizes (less than 2 μm to 50 μm) were present
within the cytoplasm of the viable (Figure 2B) and degen-
erative (Figure 2C) adrenal cortical tumor cells. Most of
the viable adrenal cortical tumor cells containing inclu-
sions resembled zona reticularis, although rare cells with
inclusions appeared similar to zona fasciculata. Inclusions
varied from 0 per cell to greater than 20. In nontumoral
adrenal tissue, inclusions were only present in the zona
fasciculata directly adjacent to the tumor (Figure 2D).
Immunostains were performed in which the viable ad-
renal cortical tumor cells expressed AE1/3 (weak, diffuse),
melan A (strong, diffuse), and inhibin (moderate, diffuse),
but were nonreactive for PAX8, CAIX, CD68, and CD163.
Degenerating cells were negative for CD68 and CD163.
Special stains demonstrated that the inclusions were
negative for Luxol fast blue performed with and without
Periodic acid-Schiff (PAS) counterstain and negative for
Table 1 Adrenalectomy findings in patients with hyperaldosteronism
Case Age Gender Medication (duration) Adrenalectomy diagnosis Spironolactone-like
bodies present
1 39 M Spironolactone (6 weeks), Eplerenone
(6 weeks with no treatment 3 weeks prior to surgery)
Adrenal cortical adenoma (1.9 cm) Diffuse
2 59 F Spironolactone (>9 months) Adrenal cortical adenoma (0.9 cm) Diffuse
3 56 M Spironolactone (>9 months) Adrenal cortical adenoma (2.8 cm) Focal
4 61 M Spironolactone (>2 months) Nodular cortical hyperplasia Focal
5 35 M Spironolactone (5 months) Adrenal cortical adenoma (1.8 cm) None
6 60 M Spironolactone (2 months with no treatment
7 months prior to surgery)
Nodular cortical hyperplasia None
7 68 M Spironolactone (>2 months) Vascular cyst None
8 60 M Eplerenone (>3 years) Adrenal cortical adenoma (1.6 cm) None
9 48 M Eplerenone (>3 months) Nodular cortical hyperplasia None
10 51 M Eplerenone (>3 years) Nodular cortical hyperplasia None
11 46 M Eplerenone (>1.5 years) Hematoma (post venus sampling) None
12 46 M Eplerenone (unknown) Lipoma None
13 43 F No treatment Adrenal cortical adenoma (2.3 cm) None
14 34 F No treatment Adrenal cortical adenoma (1.5 cm) None
15 62 M No treatment Adrenal cortical adenoma (2.3 cm) None
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pink staining (Figure 2E). A hemoglobin special stain was
performed which variably stained the inclusions olive green,
pale pink, and brick red (Figure 2F).
Ultrastructural examination using formalin-fixed tissue
revealed that most classic viable adenoma cells did not
contain dense inclusions. These cells had numerous
organelles, including slightly swollen mitochondria
and weakly electron dense lipid droplets (Figure 3A).
Some viable and degenerative adrenal cortical cells con-
tained inclusions. The size of the bodies varied and multiple
morphologies were seen in a single cell. There were some
inclusions touching the nucleus while others were in
proximity to mitochondrion or endoplasmic reticulum.Figure 1 Gross photographs of the left adrenal gland from
patient 1 conteining a well-circumscribed tan-yellow cortical
nodule measuring 1.9 cm.The inclusions had variable electron density, which may
be due to the varying amount of unsaturated lipids and/or
degenerative change (Figure 3B). A few inclusions looked
like they may have originated from degenerated mitochon-
dria due to possible remnant cristae and the presence of a
membrane (Figure 3C). However, most of the dense inclu-
sions did not have such structure. Lipofuscin granules were
seen admixed with the dense inclusions. There were several
inclusions that resembled typical spironolactone bodies
with a scroll-like membrane but without an electron dense
core present (Figure 3D). There were only a few bodies with
both a scroll-like concentric membrane and an electron
dense core (Figure 3E).
Patient 2-4
Inclusions were histologically identified in an additional
three patients. A 59 year-old female with a history of
hypertension since age 25 was started on spironolactone
25 mg once a day for more than 9 months (patient 2).
The adrenalectomy contained a 0.9 cm adrenal cortical
adenoma. Large pale eosinophilic bodies with concentric
rings were found single per cell throughout the tumor,
with minimal variation in size (Figure 2G). Ultrastructural
examination was performed using paraffin-embedded tis-
sue as no other tissue was available. Only inclusions with
scroll-like membranes without electron dense cores were
identified (Figure 3F). A 56 year-old male with a history of
poorly controlled hypertension and obesity was started on
spironolactone 100 mg twice a day for more than 9 months





Figure 2 Photomicrographs of patient 1 (A-F), patient 2 (G), and patient 4 (H). A. Nodules of adrenal cortical tumor cells separated by an
infiltrate of paler spindle cells in patient 1 (400x). B. Adrenal cortical tumor cells showing numerous brightly eosinophilic inclusions of varying
sizes in the cytoplasm. Multiple inclusions are present in each cell (400x). C. Spindle cell infiltrate composed of degenerating adrenal cortical cells
(400x). D. Inclusions were also present in the zona fasciculata directly adjacent to the tumor (400x). E. Inclusions positive for PAS, showing bright
pink staining, with Luxol Fast Blue counterstaining. There were variably sized multiple intracellular inclusions (400x). F. Hemoglobin stain with a
spectrum of staining including olive green, pale pink, and brick red inclusions. Multiple inclusions of each color were present in a single cell
(400x). G. In patient 2, large eosinophilic bodies with concentric rings were found single per cell throughout the tumor (400x). H. In patient 4, rare
large, eosinophilic, concentrically laminated bodies were seen within the zona glomerulosa (400x).
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concentrically laminated inclusions, single per cell, only in
focal areas of the tumor. A 61 year-old male with a history
of hypertension for 15 years was started on spironolactone
50 mg once a day for more than 2 months (patient 4).
Nodular cortical hyperplasia was diagnosed in the adrenal-
ectomy. Histology revealed rare eosinophilic, large, and
concentrically laminated bodies within the zona glomeru-
losa (Figure 2H).Discussion
We investigated spironolactone bodies of the adrenal
gland within a recent 2 year period in patients with
hyperaldosteronism. Spironolactone bodies occur in the
adrenal gland secondary to spironolactone treatment [1]
but have yet to be investigated in patients treated with
eplerenone, a newer aldosterone antagonist.
The incidence of spironolactone bodies within the ad-






Figure 3 Transmission electron micrographs of patient 1 (A-E) and patient 2 (F). A. Classic adenoma cells on the left. The cells on the right
contained dense inclusions (2,000x). B. Some of the cells had multiple inclusions with variable electron density (6,000x). C. This election dense
inclusion may represent a degenerated mitochondrion containing possible remnant cristae as it is surrounded by a membrane. However, most of
the dense inclusions had no lining membrane (60,000x). D. Inclusions with characteristic concentrically laminated membranes similar to those
surrounding typical spironolactone bodies, but without an electron dense core (12,000x). E. Some cells contained inclusions similar to typical
spironolactone bodies, complete with an electron dense core surrounded by concentrically laminated membranes (40,000x). F. In patient 2, using
paraffin-embedded tissue, only scroll-like inclusions without electron dense cores were identified (60,000x).
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1981 and 1985, inclusions were found within 74-100%
of patients with primary hyperaldosteronism that were
pharmacologically treated with spironolactone [3,5-7].
We detected inclusions in only 33% (4/12) of patients with
primary hyperaldosteronism treated with spironolactone
and/or eplerenone, much lower than prior studies. Re-
markably, 50% of patients treated with spironolactone
had inclusions while no patients using eplerenone alone
had inclusions. It is possible that the release of eplerenonein 2002 and its subsequent preferred use due to less
undesirable side effects have decreased the incidence
of spironolactone-like bodies.
The spironolactone bodies in some of our patients
persisted much longer than the duration for which
spironolactone bodies are thought to occur. Spirono-
lactone bodies decrease over time as spironolactone
continues to be administered [6,8]. Conn et al. found
the number of spironolactone bodies peaked 4-6 weeks
after the start of treatment after which there was a marked
Patel et al. Diagnostic Pathology 2014, 9:147 Page 6 of 7
http://www.diagnosticpathology.org/content/9/1/147decrease, with a third of patients treated for 100-170 days
having no detectable bodies [8]. These authors suggested
that the existence of bodies gradually diminishes to zero
by 170 days [8]. However, in our study, 67% of patients
treated with spironolactone alone for over 100 days had
bodies and 2 patients treated for over 270 days were found
to have either diffuse or focal bodies. The effect of dosage
on the persistence of bodies is unknown, but it is of note
that in the report by Conn et al., patients with no
inclusions received higher dosages of spironolactone [8].
Spironolactone bodies eventually disappear if medication
is discontinued [6,8]. Authors have shown that discontinu-
ation of spironolactone 18-97 days before surgery results
in no identifiable inclusion bodies [6,8]. However, patient
1 in our study discontinued medications for more than
3 weeks and yet inclusions were found. Eplerenone ad-
ministration may have resulted in these bodies occurring
longer than expected.
The ultrastructural morphology of typical spironolactone
bodies show scroll-like concentric laminations of mem-
branes with an electron-dense core [1,2,5]. Inclusion bodies
with unusual histologic features were identified in 1 of our
patients and were subsequently examined ultrastructurally,
showing a spectrum of findings. A few bodies resembling
typical spironolactone bodies were present but there were
also inclusions that had the same scroll-like appearance but
did not have a visible electron dense core typical for fully-
developed spironolactone bodies. Additionally identified
were dense inclusions that did not have the concentric lam-
inations or any membrane typical of spironolactone bodies.
The specificity of spironolactone bodies for spironolactone
treatment is under question. Several researchers have stated
that these bodies appear exclusively in aldosterone-
producing cells [8,9]. Kovacs et. al concluded that spirono-
lactone bodies are not exclusively due to spironolactone
treatment based on the presence of similar “fingerprint-like
bodies” elsewhere in the adrenal cortex secondary to
treatment with other drugs [2].
Spironolactone bodies have been histologically depicted
in the literature as typically solitary eosinophilic bodies
surrounded by a clearing within a single cell [10]. However,
1 of our specimens histologically contained numerous
inclusions which ultrastructurally were composed of
both typical spironolactone bodies and membrane-less
electron-dense inclusions in individual cells. Mete and
Asa described similar membrane-less electron-dense
inclusions in a patient with an adrenal cortical aden-
oma [11]. Unlike our case, their patient was not treated
with any aldosterone antagonist and did not have any
typical spironolactone bodies in that the inclusions
were not concentric or laminated [11]. The bodies that
these authors found were multiple per cell and histo-
logically appeared similar to those we identified. Of
note, formalin-fixed paraffin embedded tissue was used.Formalin-fixed paraffin embedded tissue has been found
by previous studies to be suboptimal for ultrastructural
examination and in 1 of our patients only revealed scroll-
like inclusions that lacked electron dense cores [12,13].
The location in which spironolactone bodies are found
is variable. Of our 3 patients that had an adrenal cortical
adenoma with inclusions bodies, 2 had inclusions only
in the tumor, while 1 had bodies predominately in the
tumor but also in the non-neoplastic adrenal tissue
adjacent to the tumor, mostly in the zona fasciculata and
rarely in the zona glomerulosa. In 1 patient with nodular
cortical hyperplasia and bodies, the inclusions were
confined to the zona glomerulosa. Similar to our results,
most authors have identified bodies in the tumor only,
while others have found bodies in the tumor and adja-
cent tissue [3,6,11].
Typical spironolactone bodies are described to be
Luxol fast blue positive and PAS negative [2,3]. They are
hypothesized to originate from the smooth endoplasmic
reticulum [2,3,14]. The inclusion is thought to be rich in
phospholipids due to Luxol fast blue staining [2,3]. The
concentric laminations have been demonstrated to con-
tain aldosterone [4]. However, we found the bodies to be
negative for Luxol fast blue and positive for PAS. Mete
and Asa also reported similar Luxol fast blue negativity
and PAS positivity [11]. Future studies are needed to
further investigate the contents of these inclusions using
more sophisticated techniques.Conclusion
In conclusion, we found the incidence rate of spironolac-
tone bodies to be far less than reported in the past, with
no inclusions identified in cases in which only eplere-
none was used. Bodies were present after their typical
life-span and were seen after medication was discon-
tinued for an extended period of time. Additionally, we
describe histologically unusual inclusions with both
classic and more uncommon ultrastructural findings of
spironolactone bodies. Surgical pathologists should be
aware of these infrequently encountered inclusions to
prevent misinterpretation and unnecessary work-up.
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